One of the top officials of Cephalosporin bulk drug maker Orchid Chemicals and Pharmaceuticals Ltd has recently confirmed about the company's plans of investing big in therapeutic segments this year.

According to the reports, Orchid Chemicals and Pharmaceuticals Ltd is planning to invest an amount of Rs. 200 crore into formulations in niche therapeutic segments this year.

In context to same, Chairman and Managing Director Mr. K. Raghavendra Rao told the reporters while speaking on the sideline of company's annual general meeting that the proposed investment in the section has been made thinking that it would efficiently support the company's entry into therapeutic segments and at the time when manufacturing process becomes difficult comparatively.

As told by the drug maker Orchid Chemicals & Pharmaceuticals today, in concern to the surrounding environment, the Tamil Nadu Pollution Control Board (TNPCB) has issued a closure notice to its Chennai-based manufacturing facility.

The TNPCB found the company’s Cephalosporin producing facility at Alathur in Chennai involved into some non-compliance in regard to the disposal of solid waste and thus they ordered to shut down their work there. Cephalosporin is basically the latest class of antibiotics that is useful for treating infections in different parts of the body.

Chennai, May 18 : Pharmaceuticals major Orchid Chemicals and Pharmaceuticals Ltd Wednesday recommended 30 percent dividend for the year 2010-11.

The company closed last fiscal with a consolidated revenue of Rs. 1,786 crore and a net profit of Rs. 156 crore, as compared to Rs. 1,343 crore and a net profit of around Rs. 339 crore in 2009-2010.

During 2009-2010, the company sold its injectibles business and hence the profit figures of the current year are not exactly comparable.

Orchid Chemicals & Pharmaceuticals Ltd was established in the year 1992 as a 100% Export Oriented Unit. Commencing operations in February 1994, company achieved rapid growth to emerge as the one of the largest company in the Indian pharmaceutical industry in a short span of years. Company employs over 4000 people; over 700 of them are scientists, technologists and other professionals.

was established in the year 1992 as a 100% Export Oriented Unit. Commencing operations in February 1994, company achieved rapid growth to emerge as the one of the largest company in the Indian pharmaceutical industry in a short span of years. Company employs over 4000 people; over 700 of them are scientists, technologists and other professionals. Company has long-term exclusive agreements with reputed companies such as Apotex, Par, Alpharma, Stada and Mayne for distribution of Orchid’s products in the regulated markets of US and Europe.

Technical analyst Anil Singhvi has maintained 'buy' rating on Orchid Chemicals & Pharmaceuticals Limited stock with an intra-day target of Rs 295.

According to analyst, the investors can buy the stock with stop loss of Rs 277.

The stock of the company, on December 22, closed at Rs 281.20 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 344.40 and a low of Rs 128 on BSE.

Current EPS is -72.43.

Buy Orchid Chemicals With Target Of Rs 340 Stock market analyst Parsh Zaveri of Zaveri Investments has maintained 'buy' rating on Orchid Chemicals & Pharmaceuticals Limited stock with a target of Rs 340.

The stock can be bought with a stop loss of Rs 315.

The stock of the company, on Nov 23, closed at Rs 321.95 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 344.40 and a low of 128 on BSE.

Current EPS is -72.43.

Stock market analyst Kunal Saraogi has maintained 'buy' rating on Orchid Chemicals & Pharmaceuticals Limited stock with a target of Rs 210.

According to analyst, the interested investors can buy the stock with stop loss of Rs 184.

The stock of the company, on Sep 16, closed at Rs 188.55 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 239.40 and a low of Rs 128 on BSE.

Current EPS is -76.52.

Technical Analyst Ashwani Gujral has maintained 'sell' rating on Orchid Chemicals & Pharmaceuticals Ltd stock with a target of Rs 112.

According to Mr. Singhvi, interested traders can sell the stock with stop loss of Rs 138.

Today, the stock opened at Rs 1108.85 on the Bombay Stock Exchange (BSE). The share price has seen a 52-week high of Rs 1138 and a low of Rs 688 on BSE.

Current EPS & P/E ratio stood at 7.85 and 20.95 respectively.

Hospira, the American pharma firm, has decided to buy the core business segment, ‘generic injectable pharmaceuticals,’ from the Chennai-based Orchid Chemicals & Pharmaceuticals Ltd, in a deal worth $400 million.

The Orchid Chemicals & Pharmaceuticals Ltd had started the company 4 years back with an investment of Rs 650 crore. But, due to the liquidity problems and the increasing competition in the sector, the company had to sell the unit.

Chennai, Dec 16 : Orchid Chemicals may not have sold the 'family silver' - its $90 million generic injectible business - to the $3.6 billion Hospira Inc - but has sold at least a pearl.

The whole deal has been codenamed within the company as Project Oyster.

Orchid Chemical Wednesday announced the sale of its generic injectible business to Hospira for $400 million.

Chennai, Dec 16 : City-based Cephalosporin bulk drug major, Orchid Chemicals and Pharmaceuticals Limited, will utilise $400 million received from selling its generic injectible business to pay off debt, expand its plants and look at inorganic growth opportunities, said a top company official.

Stock market analysts have maintained 'buy' rating on Orchid Chemicals & Pharmaceuticals Ltd with an intraday target of Rs 193.

According to them, interested traders can purchase the stock above Rs 191 with a strict stop loss of Rs 185.

If the bourses remain on the positive track, then the stock price will hit a target above Rs 195.

Shares of the company, on Wednesday (Nov 25), closed at Rs 189.65 on the Bombay Stock Exchange (BSE). The share price has seen a 52-week high of Rs 183.40 and a low of Rs 56.50 on BSE.

Chennai-based drug manufacturer Orchid Chemicals & Pharmaceuticals has received the final Abbreviated New Drug Application (ANDA) nod from the US Food and Drug Administration for its Zaleplon capsules.   
 
The capsules which are available in strengths of 5 mg and 10 mg, are used in treating insomnia.

With this approval, the total ANDA approval count of Orchid has gone up to 37 while, the total ANDA filings stand at 58.     

Drug firm Orchid Chemicals & Pharmaceuticals has informed that the company has received final nod from US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Zaleplon Capsules.      The drug is used for the treatment of insomnia.

Orchid Chemicals stated in a release that it will sell the Zaleplon Capsules in the strengths of 5 mg and 10 mg.

The company statement said that with this approval, the total ANDA approval count of Orchid has gone up to 37, while the total ANDA filings stand at 58.

Drug firm Orchid Chemicals & Pharmaceuticals has informed that the company has received final nod from US Food and Drug Administration (USFDA) for its drug Sumatriptan Succinate tablets.

The drug is generic version of GlaxoSmithKline PLC's Imitrex, which is used for the treatment of migraine attacks.

Orchid Chemicals further stated in a release that it will sell the sumatriptan succinate tablets in the strengths of 25 mg, 50 mg and 100 mg.

Orchid Chemical can be purchased around Rs 240 by day traders in today’s trading session with a stop loss of Rs 237 for achieving an intraday target of Rs.245.
If the stock markets remain on positive track, the stock can also achieve the next intraday target of Rs 252.

The company’s shares closed at Rs 246.45 on Wednesday. The stock has touched 52-week high of Rs 328 and low of Rs 176 on BSE.
The stock has potential to rise to the target price as the company has good growth prospects considering its projects under implementation and aggressive growth plans.